Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
